Medexus Pharmaceuticals Inc(DE:P731)
€3.56+0.04 (+1.14%)
DE:P731
Medexus Pharmaceuticals Inc financials statements
€3.56
At close:+0.04 (+1.14%)
Medexus Pharmaceuticals Inc (P731) Ratios
2 Followers
Medexus Pharmaceuticals Inc Ratios
DE:P731's free cash flow for Q2 2027 was C$5.09M. For the 2027 fiscal year, DE:P731's free cash flow was decreased by C$-30.22K and operating cash flow was C$5.12M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.19 | 1.09 | 0.65 | 0.82 | 1.47 |
| Quick Ratio | 0.57 | 0.63 | 0.44 | 0.46 | 1.10 |
| Cash Ratio | 0.12 | 0.08 | 0.16 | 0.21 | 0.59 |
| Solvency Ratio | 0.07 | 0.04 | 0.05 | 0.03 | -0.16 |
| Operating Cash Flow Ratio | 0.35 | 0.28 | -0.01 | -0.02 | 0.13 |
| Short-Term Operating Cash Flow Coverage | 8.53 | 1.19 | -0.03 | -0.06 | 0.38 |
| Net Current Asset Value | C$ -34.51M | C$ -52.91M | C$ -114.73M | C$ -102.71M | C$ -71.92M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.15 | 0.32 | 0.59 | 0.39 | 0.38 |
| Debt-to-Equity Ratio | 0.45 | 1.65 | 4.22 | 3.08 | 3.13 |
| Debt-to-Capital Ratio | 0.31 | 0.62 | 0.81 | 0.76 | 0.76 |
| Long-Term Debt-to-Capital Ratio | 0.29 | 0.53 | 0.54 | 0.69 | 0.65 |
| Financial Leverage Ratio | 3.01 | 5.14 | 7.19 | 7.83 | 8.24 |
| Debt Service Coverage Ratio | 1.69 | 0.65 | 0.31 | 0.52 | -0.87 |
| Interest Coverage Ratio | 1.12 | 0.81 | 0.56 | -1.23 | -0.14 |
| Debt to Market Cap | 0.22 | 1.38 | 2.64 | 0.95 | 0.39 |
| Interest Debt Per Share | 0.85 | 2.83 | 5.42 | 3.45 | 4.38 |
| Net Debt to EBITDA | 1.24 | 2.32 | 4.77 | 2.79 | -1.39 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.78% | 52.64% | 55.54% | 49.45% | 52.73% |
| EBIT Margin | 2.95% | 11.91% | 7.92% | 10.96% | -39.56% |
| EBITDA Margin | 12.75% | 17.05% | 14.93% | 19.77% | -29.63% |
| Operating Profit Margin | 5.87% | 9.55% | 7.04% | -19.55% | -1.73% |
| Pretax Profit Margin | -2.29% | 0.09% | -4.66% | -4.98% | -39.54% |
| Net Profit Margin | -2.41% | -0.19% | 1.13% | -3.75% | -35.48% |
| Continuous Operations Profit Margin | -2.41% | -0.19% | 1.13% | -3.75% | -35.48% |
| Net Income Per EBT | 105.28% | -201.89% | -24.22% | 75.37% | 89.72% |
| EBT Per EBIT | -38.97% | 0.98% | -66.21% | 25.47% | 2289.32% |
| Return on Assets (ROA) | -1.63% | -0.14% | 0.76% | -2.07% | -19.03% |
| Return on Equity (ROE) | -4.89% | -0.71% | 5.44% | -16.18% | -156.87% |
| Return on Capital Employed (ROCE) | 6.23% | 12.06% | 15.70% | -18.96% | -1.27% |
| Return on Invested Capital (ROIC) | 6.08% | -20.71% | -1.74% | -11.55% | -1.01% |
| Return on Tangible Assets | -3.20% | -0.26% | 1.51% | -5.54% | -45.96% |
| Earnings Yield | -2.37% | -0.60% | 3.82% | -4.71% | -23.54% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.69 | 4.70 | 3.64 | 5.32 | 3.37 |
| Payables Turnover | 5.46 | 6.91 | 4.73 | 2.57 | 2.53 |
| Inventory Turnover | 1.35 | 1.74 | 2.10 | 1.82 | 2.57 |
| Fixed Asset Turnover | 235.38 | 145.31 | 120.24 | 62.82 | 100.20 |
| Asset Turnover | 0.67 | 0.73 | 0.67 | 0.55 | 0.54 |
| Working Capital Turnover Ratio | -30.40 | -6.73 | -4.25 | 20.18 | 6.50 |
| Cash Conversion Cycle | 258.36 | 234.53 | 196.65 | 127.78 | 106.61 |
| Days of Sales Outstanding | 54.59 | 77.58 | 100.27 | 68.56 | 108.43 |
| Days of Inventory Outstanding | 270.57 | 209.78 | 173.53 | 200.99 | 142.17 |
| Days of Payables Outstanding | 66.81 | 52.83 | 77.15 | 141.77 | 143.99 |
| Operating Cycle | 325.16 | 287.36 | 273.80 | 269.55 | 250.60 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.58 | 0.84 | -0.07 | -0.06 | 0.33 |
| Free Cash Flow Per Share | 0.12 | 0.83 | -0.09 | -0.46 | -0.38 |
| Dividend Paid and CapEx Coverage Ratio | 1.25 | 70.35 | -3.99 | -0.15 | 0.47 |
| Capital Expenditure Coverage Ratio | 1.25 | 70.35 | -3.99 | -0.15 | 0.47 |
| Operating Cash Flow Coverage Ratio | 0.85 | 0.38 | -0.02 | -0.02 | 0.09 |
| Operating Cash Flow to Sales Ratio | 0.19 | 0.17 | -0.01 | -0.02 | 0.06 |
| Free Cash Flow Yield | 3.69% | 51.33% | -5.65% | -14.56% | -4.76% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -44.57 | -167.93 | 26.18 | -21.22 | -4.25 |
| Price-to-Sales (P/S) Ratio | 1.02 | 0.32 | 0.30 | 0.80 | 1.51 |
| Price-to-Book (P/B) Ratio | 2.06 | 1.19 | 1.42 | 3.43 | 6.66 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 27.10 | 1.95 | -17.70 | -6.87 | -21.00 |
| Price-to-Operating Cash Flow Ratio | 5.34 | 1.92 | -22.13 | -51.77 | 23.83 |
| Price-to-Earnings Growth (PEG) Ratio | 0.25 | 1.50 | -0.18 | 0.23 | -0.01 |
| Enterprise Value Multiple | 9.21 | 4.18 | 6.76 | 6.82 | -6.48 |
| Enterprise Value | 116.57M | 80.58M | 109.02M | 103.42M | 152.95M |
| EV to EBITDA | 9.21 | 4.18 | 6.76 | 6.82 | -6.48 |
| EV to Sales | 1.17 | 0.71 | 1.01 | 1.35 | 1.92 |
| EV to Free Cash Flow | 31.34 | 4.37 | -60.36 | -11.63 | -26.75 |
| EV to Operating Cash Flow | 6.18 | 4.31 | -75.50 | -87.65 | 30.36 |
| Tangible Book Value Per Share | -0.73 | -1.98 | -5.36 | -5.13 | -4.54 |
| Shareholders’ Equity Per Share | 1.52 | 1.36 | 1.12 | 0.91 | 1.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.05 | 3.02 | 1.24 | 0.25 | 0.10 |
| Revenue Per Share | 3.07 | 5.06 | 5.41 | 3.94 | 5.24 |
| Net Income Per Share | -0.07 | -0.01 | 0.06 | -0.15 | -1.86 |
| Tax Burden | 1.05 | -2.02 | -0.24 | 0.75 | 0.90 |
| Interest Burden | -0.78 | 0.01 | -0.59 | -0.45 | 1.00 |
| Research & Development to Revenue | 0.09 | 0.07 | 0.03 | 0.10 | 0.06 |
| SG&A to Revenue | 0.40 | 0.25 | 0.34 | 0.38 | 0.24 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 |
| Income Quality | -7.88 | -87.45 | -1.18 | 0.41 | -0.18 |
Currency in CAD

